186 related articles for article (PubMed ID: 30617130)
1. Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Ramchandren R; Advani RH; Ansell SM; Bartlett NL; Chen R; Connors JM; Feldman T; Forero-Torres A; Friedberg JW; Gopal AK; Gordon LI; Kuruvilla J; Savage KJ; Younes A; Engley G; Manley TJ; Fenton K; Straus DJ
Clin Cancer Res; 2019 Mar; 25(6):1718-1726. PubMed ID: 30617130
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM; Jurczak W; Straus DJ; Ansell SM; Kim WS; Gallamini A; Younes A; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Oki Y; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Chen R; Ramchandren R; Zinzani PL; Cunningham D; Rosta A; Josephson NC; Song E; Sachs J; Liu R; Jolin HA; Huebner D; Radford J;
N Engl J Med; 2018 Jan; 378(4):331-344. PubMed ID: 29224502
[TBL] [Abstract][Full Text] [Related]
3. [Brentuximab Vedotin, Doxorubicin, Vinblastine, Dacarbazine(A+AVD)Therapy for Classical Hodgkin Lymphoma- A Single-Institution Experience].
Kobayashi M; Yokoyama E; Izumiyama K; Mori A; Saito M; Morioka M; Kondo T
Gan To Kagaku Ryoho; 2023 Sep; 50(9):979-983. PubMed ID: 37800293
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin with AVD for stage II-IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial.
Rubinstein PG; Moore PC; Bimali M; Lee JY; Rudek MA; Chadburn A; Ratner L; Henry DH; Cesarman E; DeMarco CE; Costagliola D; Taoufik Y; Ramos JC; Sharon E; Reid EG; Ambinder RF; Mitsuyasu R; Mounier N; Besson C; Noy A; ;
Lancet Haematol; 2023 Aug; 10(8):e624-e632. PubMed ID: 37532416
[TBL] [Abstract][Full Text] [Related]
5. Estimated impact of ECHELON-1 overall survival on productivity costs in stage III/IV classical Hodgkin lymphoma in the United States.
Phillips T; Liu N; Bloudek B; Migliaccio-Walle K; Reynolds J; Burke JM
J Manag Care Spec Pharm; 2023 Dec; 29(12):1312-1320. PubMed ID: 37921077
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin's lymphoma: a probabilistic analysis.
Raymakers AJN; Costa S; Cameron D; Regier DA
BMC Cancer; 2020 Oct; 20(1):992. PubMed ID: 33050897
[TBL] [Abstract][Full Text] [Related]
7. Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort.
Bowers JT; Anna J; Bair SM; Annunzio K; Epperla N; Pullukkara JJ; Gaballa S; Spinner MA; Li S; Messmer MR; Nguyen J; Ayers EC; Wagner CB; Hu B; Di M; Huntington SF; Furqan F; Shah NN; Chen C; Ballard HJ; Hughes ME; Chong EA; Nasta SD; Barta SK; Landsburg DJ; Svoboda J
Blood Adv; 2023 Nov; 7(21):6630-6638. PubMed ID: 37595053
[TBL] [Abstract][Full Text] [Related]
8. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R; Sureda A; de la Cruz F; Canales M; Gonzalez AP; Pinana JL; Rodriguez A; Gutierrez A; Domingo-Domenech E; Sanchez-Gonzalez B; Rodriguez G; Lopez J; Moreno M; Rodriguez-Salazar MJ; Jimenez-Cabrera S; Caballero MD; Martinez C
Ann Oncol; 2019 Apr; 30(4):612-620. PubMed ID: 30657848
[TBL] [Abstract][Full Text] [Related]
9. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma.
Steiner RE; Hwang SR; Khurana A; Habermann TM; Epperla N; Annunzio K; Allen PB; Baird K; Paulino D; Alderuccio JP; Lossos IS; David K; Evens AM; Pandya K; Bair SM; Kamdar M; Ba Aqeel S; Torka P; Lynch R; Smith S; Feng L; Noorani M; Ahmed S; Nair R; Vega F; Wu S; Fang P; Pinnix CC; Gunther JR; Dabaja BS; Lee HJ
Blood Adv; 2023 Dec; 7(24):7485-7493. PubMed ID: 37603594
[TBL] [Abstract][Full Text] [Related]
10. Acute liver failure secondary to ABVD use.
Eslami A; Mathur AD; Jha KK; Wang H
BMJ Case Rep; 2018 Jul; 2018():. PubMed ID: 30061135
[TBL] [Abstract][Full Text] [Related]
11. Incorporating Monoclonal Antibodies into the First-Line Treatment of Classical Hodgkin Lymphoma.
Vassilakopoulos TP; Liaskas A; Pereyra P; Panayiotidis P; Angelopoulou MK; Gallamini A
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685994
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of brentuximab vedotin in Hodgkin lymphoma: a systematic review.
Arabloo J; Azari S; Gorji HA; Rezapour A; Alipour V; Ehsanzadeh SJ
Eur J Clin Pharmacol; 2023 Nov; 79(11):1443-1452. PubMed ID: 37656182
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma.
Huntington SF; von Keudell G; Davidoff AJ; Gross CP; Prasad SA
J Clin Oncol; 2018 Oct; 36(33):JCO1800122. PubMed ID: 30285558
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma.
Allen PB; Savas H; Evens AM; Advani RH; Palmer B; Pro B; Karmali R; Mou E; Bearden J; Dillehay G; Bayer RA; Eisner RM; Chmiel JS; O'Shea K; Gordon LI; Winter JN
Blood; 2021 Mar; 137(10):1318-1326. PubMed ID: 32992341
[TBL] [Abstract][Full Text] [Related]
15. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY).
Gibb A; Pirrie SJ; Linton K; Warbey V; Paterson K; Davies AJ; Collins GP; Menne T; McKay P; Fields PA; Miall FM; Nagy E; Wheatley K; Reed R; Baricevic-Jones I; Barrington S; Radford J
Br J Haematol; 2021 Apr; 193(1):63-71. PubMed ID: 32926420
[TBL] [Abstract][Full Text] [Related]
16. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
Lynch RC; Ujjani CS; Poh C; Warren EH; Smith SD; Shadman M; Till B; Raghunathan VM; Alig S; Alizadeh AA; Gulhane A; Chen DL; Tseng Y; Coye H; Shelby M; Ottemiller S; Keo S; Verni K; Du H; Vandermeer J; Gaston A; Rasmussen H; Martin P; Marzbani E; Voutsinas J; Gopal AK
Blood; 2023 May; 141(21):2576-2586. PubMed ID: 36913694
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of novel therapies in Hodgkin lymphoma: proceed with caution.
Bartlett NL
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):317-323. PubMed ID: 29222273
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Zinzani PL; Santoro A; Gritti G; Brice P; Barr PM; Kuruvilla J; Cunningham D; Kline J; Johnson NA; Mehta-Shah N; Manley T; Francis S; Sharma M; Moskowitz AJ
J Clin Oncol; 2019 Nov; 37(33):3081-3089. PubMed ID: 31398081
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Bleomycin Deficit on Survival in Hodgkin's Lymphoma Patients: A Retrospective Study.
Soldi LR; Rabelo DH; da Silva PHR; Silva VLC; Silva MJB
Cancer Treat Res Commun; 2024; 38():100790. PubMed ID: 38241969
[TBL] [Abstract][Full Text] [Related]
20. Tumor Flare Reaction in a Classic Hodgkin Lymphoma Patient Treated With Brentuximab Vedotin and Tislelizumab: A Case Report.
Zhu C; Zhao Y; Yu F; Huang W; Wu W; He J; Cai Z; He D
Front Immunol; 2021; 12():756583. PubMed ID: 35095839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]